Research and Scholarly Activity

The Division of Allergy,Immunology and Rheumatology is actively engaged in basic and clinical research. The Allergy/Immunology Laboratory in the Children's Research Institute focuses on HIV, neonatal immunology, primary immunodeficiency diseases, inflammatory cytokines following exposure to marine toxins and studies of T cell responses to vaccines.

Current Research Projects
  • 5 RO1AI47723-06; Impact of HIV-1 Genotype on Therapy Response in Children: The major goals for this project are to determine structure-function relationships between HIV-1 protease and p7nc from patients treated with combination therapies that include protease inhibitors.
  • 1R01AI100147-01; The Effect of Breastfeeding on Immunologic Priming in Infants: Investigation of the effects of breastfeeding on the innate and adaptive immune response by examination of innate immune activation markers and B cell receptor repertoire.
  • 1R01 DA031017: Substance use and immunity function in HIV+ adolescents by systems biology: The goal is to examine the impact of substance use among HIV+ adolescents using a systems biology approach
  • 2 U01 HD040533-12 NIH/NICHD: Adolescent Medicine Leadership Group (AMLG)
    The major goals for this project are to implement an Adolescent Medicine Leadership Group (AMLG)

    • 2 U01 HD040533-12 ATN 061:  Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/ritonavir (ATV/r).  The goal of this study is to determine if the immunologic benefits of early initiation of treatment of HIV can be maintained or enhanced during de-intensification to ATV/r.
    • 2 U01 HD040533-12 ATN 081: Treatment De-intensification and Residual HIV-1 in Youth.  The goal of this study is to examine the effect of early treatment followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of replication-competent CD4+ T cell Human Immunodeficiency Virus (HIV)-1 reservoirs or cell-associated infectivity (CAI) and persistent low-level viremia (LLV), and their contribution to successful long-term control of HIV-1 replication among HIV-1 infected adolescents and young adults.
    • 2 U01 HD040533-12 ATN 083: Longitudinal changes in cardiovascular risk markers among adolescents newly infected with HIV.  The goal is to assess plasma biomarkers that predict cardiovascular risks in HIV-infected adolescents.
    • 2 U01 HD040533-12 ATN 101: Assessment of Inflammatory Markers Associated with Neurocognitive Impairment in HIV-infected Adolescents.  The goal is to identify biomarkers of early neurocogntive impairment in HIV-infected youth who are not receiving antiretroviral therapy compared to those that initiate therapy prior to DHHS guidelines.
  • Florida Department of Health Aquatic Toxins Program: The goal of this study is to determine the effect of fresh water toxins on human immunity.
Clinical Trials
  • Hizentra CSL Behring: Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning from Vivaglobin® (16% SCIG product) to Hizentra® (20% SCIG product).
  • CSL Behring - Protocol # 05-01-I: Phase IV Trial Evaluating Health-Related Quality of Life and Serious Bacterial Infections in Subjects with Primary Immunodeficiency Disorder (PIDD) Treated with Subcutaneous Immune Globulin Following Conversion from Intravenous Immune Immune Globulin
  • UO1-AI-1059-86-01 NI H/NIAID: Placebo controlled study of effects by probiotics on HIV-associated inflammation. A clinical trial to determine the impact of probiotics on inflammation in HIV-infected subects.
Recent Publications
  • Wasserman, R, Church, J, Peter, H, Sleasman, JW, Melamed, I, Stein, M, Bichler, J Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. EUFEPS 2009 June; 37 (4):272-278.
  • Rudy B, Sleasman JW, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK Short-Cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses 25 (6) Jun 21 2009.555-561.
  • Ho S, Perez E, Rose S, Lowe A, Smith L, Lawrence M, Dunn B, Ma C, Sleasman JW, Goodenow MM Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. AIDS 23 (12) Jul 21 2009. Epub.
  • Dorsey M, Petrovic A, Morrow M, Dishaw L Sleasman JW, FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Immunologic Research 44 (1-3) Jul 2009.179-184.
Recent Abstracts
  • Dorsey MJ, Morrow, MR, Sleasman JW. differential Expression of Naïve Phenotype T Regulatory Cells in Allergic Asthmatics vs. Health Age-matched Controls. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
  • Duff CM, Faulkner E, Schirm Z, Lang J, Rodriguez CA, Sleasman JW. Effective Use of Subcutaneous Immune Globulin (SCIG) for an Infant with X-linked Agammaglobulinemia (X-LA). American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
  • Chinratanapisit S, Wallet MA, Saporta SR, Ghaffari G, Rodriguez CA, Goodenow MM, Sleasman JW. Measurements of Plasma Lipopolysacharide (LPS), Endotoxin Core IgM Antibody (EndoCAb), Soluble CD14 (sCD14), TNFa, and Soluble CD62L (sCD62L) Levels to Assess Microbial Translocation and Immune Activation in HIV-Infected Children and Adolescents. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
  • Sriaroon P, Morrow MR, Hudey SN, Goodenow MM, Sleasman JW. Memory CD27+ B220- B Cell Subpopulation is decreased in Both Systemic Lupus Erythematosus (SLE) and Common Variable Immune Deficiency (CVID). American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting, March 13-17, 2009.
  • McMahon DF, Watkins SM, Reich A, Kellogg DA, Gonzalez BE, Sleasman JW. A Cluster of Cases of Cutaneous Rashes in Swimmers Exposed to Freshwater Spring-fed Rivers in Northern Florida. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.